Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Iovance Biotherapeutics (IOVA) over the last 11 years, with Q3 2025 value amounting to $10.8 million.

  • Iovance Biotherapeutics' Capital Expenditures rose 37395.1% to $10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.7 million, marking a year-over-year increase of 17501.44%. This contributed to the annual value of $11.1 million for FY2024, which is 5034.1% down from last year.
  • According to the latest figures from Q3 2025, Iovance Biotherapeutics' Capital Expenditures is $10.8 million, which was up 37395.1% from $7.5 million recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Capital Expenditures high stood at $10.8 million for Q3 2025, and its period low was $442000.0 during Q2 2024.
  • Its 3-year average for Capital Expenditures is $5.3 million, with a median of $4.2 million in 2024.
  • Its Capital Expenditures has fluctuated over the past 5 years, first tumbled by 9403.27% in 2024, then surged by 158800.9% in 2025.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' Capital Expenditures stood at $3.5 million in 2023, then increased by 18.11% to $4.2 million in 2024, then soared by 160.17% to $10.8 million in 2025.
  • Its Capital Expenditures stands at $10.8 million for Q3 2025, versus $7.5 million for Q2 2025 and $6.2 million for Q1 2025.